Effectiveness of Indapamide Prolonged‐Release and Perindopril Versus Perindopril Monotherapy for Treated Uncontrolled Hypertension: A Target Trial Emulation
Pharmacoepidemiology and Drug Safety · 2026
DOI: 10.1002/pds.70295 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Pharmacoepidemiology and Drug Safety, 2026. Verfasst von Céline Darricarrere und 8 weiteren Autor:innen. Beteiligte Einrichtung: Servier, Suresnes, France. Hauptthemen laut MEDLINE: Perindopril, Indapamide, Antihypertensive Agents, Hypertension. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Servier.
Abstract (Originalsprache)
Objective
To assess the effectiveness of indapamide prolonged release and perindopril in combination using blood pressure (BP) records collected in routine practice.
Methods
Using a target trial emulation framework, an observational retrospective cohort study was conducted. The data source was the United Kingdom's CPRD Aurum general practice database. Adults with systolic BP (SBP) ≥ 145 mmHg treated with perindopril 4/5 mg for ≥ 4 weeks at a stable dose who either added indapamide 1.5 mg to perindopril ( n = 193) or continued on perindopril monotherapy ( n = 14 571) were included. Balance between treatment arms was achieved with propensity score matching; results were explored in additional analyses using different eligibility criteria and alternative statistical methodologies. The primary outcome was change in SBP from baseline to Week 8 between indapamide added to perindopril versus perindopril monotherapy.
Results
In the primary analysis, indapamide added to perindopril yielded an additional SBP reduction of −6.3 mmHg (95% confidence interval [CI] −8.7 to −3.9) over perindopril monotherapy at Week 8. Results of additional analyses were consistent with the main analysis, but effect estimates varied due to diverse underlying assumptions.
Conclusions
Target trial emulation allowed assessment of antihypertensive treatment effectiveness, and indapamide plus perindopril yielded clinically meaningful decreases in SBP over perindopril monotherapy. Secondary and sensitivity analyses support that these findings were robust.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Servier, Suresnes, France.
- RTI Health Solutions, Barcelona, Spain.
- The Center for Health Policy and Health Services Research, Henry Ford Health System, Detroit, Michigan, USA.
- IT&M Stats, Neuilly-sur-Seine, France.
- R&D Life Cycle Management, Suresnes, France.
ORCID-Profile: Céline Darricarrere, Virginie Simon, Manel Pladevall-Vila, Morgane Ballon, Jaume Aguado, Xabier Garcia-Albeniz
Förderung
- Servier
Zitieren
APA
Darricarrere, C., Simon, V., Pladevall-Vila, M., Jacquot, E., Ballon, M., Mangin, M., Procureur, D., Aguado, J., & Garcia-Albeniz, X. (2026). Effectiveness of Indapamide Prolonged‐Release and Perindopril Versus Perindopril Monotherapy for Treated Uncontrolled Hypertension: A Target Trial Emulation. Pharmacoepidemiology and Drug Safety. https://doi.org/10.1002/pds.70295
Vancouver
Darricarrere C, Simon V, Pladevall-Vila M, Jacquot E, Ballon M, Mangin M, et al. Effectiveness of Indapamide Prolonged‐Release and Perindopril Versus Perindopril Monotherapy for Treated Uncontrolled Hypertension: A Target Trial Emulation. Pharmacoepidemiology and Drug Safety. 2026. doi:10.1002/pds.70295
BibTeX
@article{Darricarrere2026,
author = {Darricarrere, Céline and Simon, Virginie and Pladevall-Vila, Manel and Jacquot, Emmanuelle and Ballon, Morgane and Mangin, Marie and Procureur, Dominique and Aguado, Jaume and Garcia-Albeniz, Xabier},
title = {Effectiveness of Indapamide Prolonged‐Release and Perindopril Versus Perindopril Monotherapy for Treated Uncontrolled Hypertension: A Target Trial Emulation},
journal = {Pharmacoepidemiology and Drug Safety},
year = {2026},
doi = {10.1002/pds.70295}
}
EUVIMED